Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 July 2021Website:
http://www.rallybio.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:19:31 GMTDividend
Analysts recommendations
Institutional Ownership
RLYB Latest News
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the American Society of Human Genetics.
Rallybio (RLYB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RallyBio (RLYB) surges by 83% following the announcement of a partnership with J&J to create new treatments aimed at lowering the risk of FNAIT in expectant mothers, accompanied by a $6.6 million investment from J&J.
Rallybio stock is surging today after revealing a partnership with Johnson & Johnson. Johnson & Johnson is providing backing for Rallybio's FNAIT therapy development.
Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in patients, while RLYB116 showed a reduction in Free C5 greater than 99%. The company has a cash balance of $138mn and a cash runway of approximately 6 quarters.
The mean of analysts' price targets for Rallybio Corporation (RLYB) points to a 202.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What type of business is Rallybio?
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
What sector is Rallybio in?
Rallybio is in the Healthcare sector
What industry is Rallybio in?
Rallybio is in the Biotechnology industry
What country is Rallybio from?
Rallybio is headquartered in United States
When did Rallybio go public?
Rallybio initial public offering (IPO) was on 29 July 2021
What is Rallybio website?
https://www.rallybio.com
Is Rallybio in the S&P 500?
No, Rallybio is not included in the S&P 500 index
Is Rallybio in the NASDAQ 100?
No, Rallybio is not included in the NASDAQ 100 index
Is Rallybio in the Dow Jones?
No, Rallybio is not included in the Dow Jones index
When was Rallybio the previous earnings report?
No data
When does Rallybio earnings report?
The next expected earnings date for Rallybio is 08 November 2024